Monograph Capital Advisors

Investment decisions are led by Managing Partners Tim Clayton and Freddie Dear. Clayton brings a physician-scientist perspective from his tenure at AstraZeneca's MedImmune division, while Dear contributes strategy and operational expertise from the same organization. The firm maintains a flat partnership structure with a small investment committee that evaluates each opportunity against the firm's platform-biotech thesis.

Monograph deploys initial checks of $20 million to $40 million into a concentrated portfolio of 8-12 companies, with reserves of up to $100 million per position to support follow-on financings. The firm typically leads or co-leads rounds and takes active board seats. It favors company creation around specific academic discoveries and targets platform biotechs — companies with multiple therapeutic programs — rather than single-asset bets.

Monograph's core geographic focus is the United Kingdom and continental Europe, where the firm believes transformative academic science has been historically underserved by long-duration venture capital. The firm selectively invests in the United States when opportunities align with its platform-building strategy and syndicate preferences.

Monograph's founding partners Tim Clayton and Freddie Dear are both former executives at AstraZeneca's biologics research and development arm, MedImmune. This lineage informs the firm's clinical-development operating model, but Monograph operates as an independent investment firm with no formal affiliation or exclusive pipeline arrangement with AstraZeneca.

No. Monograph's stated strategy explicitly targets platform biotechnology companies — those developing multiple therapeutic candidates against validated biological pathways. The firm avoids single-asset stories where the entire enterprise value rests on one preclinical or early-clinical program, as these do not align with its concentration model and multi-decade holding period.